Six classes for T2DM. Two of them save lives. Four just lower glucose. clinical medicine love asking which is which.
DRUG DUEL
The Six Classes
Tap any card to flip it. Front = mechanism + clue. Back = side effects + the trap clinical medicine love.
PICK A SIDE
Hypoglycemia Battle
Two camps. One forces insulin out regardless of glucose. The other only acts when sugar is high. The split is the most testable fact on the page.
Hypoglycemia Risk · the insulin-pushers
These drugs force insulin into the bloodstream whether or not glucose is high. Skip a meal, drink alcohol, or have CKD on board, and the sugar crashes.
Sulfonylureasglipizide, glyburide, glimepiride · close K+/ATP channels in beta cells
Meglitinidesrepaglinide, nateglinide · same target as sulfonylureas, shorter half-life
Insulinany exogenous insulin (basal or rapid) · dose-independent of food intake
Mechanism trap: Sulfonylureas and meglitinides bypass the glucose checkBeta cells normally only release insulin when ATP rises (which only happens when glucose is high). These drugs force the K+/ATP channel shut without waiting for glucose · so insulin dumps even at glucose 70. on the beta cell. Insulin obviously doesn't care about glucose at all. Elderly + CKD + skipped meal = preventable hypoglycemic coma.
No Hypoglycemia · the glucose-dependent crew
These drugs only work when sugar is high, or work via a non-insulin pathway. clinical medicine love this distinction · pick from this side when hypoglycemia would be catastrophic.
TZDs−glitazone drugs · PPAR-gamma sensitizes, no insulin push
Why no hypoglycemia: GLP-1 agonists and DPP-4i only trigger insulin when glucose is already elevated (the incretin axis is glucose-sensing by design). Metformin, SGLT2i, and TZDs work through pathways that don't push insulin out at all. Mix any of these freely · they don't crash sugar even with skipped meals.
FIRST-LINE · CHEAP
Biguanides
a.k.a. metformin
metformin (the only one that matters)
Inhibits Complex I of the ETCComplex I = first step of electron transport. Block it in liver mitochondria, ATP drops locally, and gluconeogenesis (energy-expensive) stalls. Less liver-made glucose = lower fasting sugar. in liver → less hepatic gluconeogenesis. Also boosts insulin sensitivity in muscle.
No hypoglycemia. Weight neutral or weight loss. Cuts CV mortality modestly.
tap to flip →
Side Effects
GI upset (take with food). B12 deficiency on chronic use. Lactic acidosis (rare but lethal · the tissue can't use oxygen properly because Complex I is blocked).
Hold or Don't Use
eGFR < 30. Liver failure. Alcoholism. IV contrast within 48h. Major surgery. Acute illness with hypoperfusion.
Board Trap
Patient gets contrast-CT and you didn't hold metformin? Lactic acidosis on board day. Hold for 48h around contrast.
DANGEROUS · HYPOGLYCEMIA
Sulfonylureas
−ide / −izide
glipizide, glyburide, glimepiride
Closes K+/ATP channelsBeta cells normally open these channels when glucose is LOW (so they don't release insulin). Sulfonylureas slam them shut regardless of glucose · the cell depolarizes, calcium floods in, insulin dumps out. No glucose check. on beta cells → depolarization → insulin release regardless of glucose.
Forces insulin out even when sugar is normal · that's why hypoglycemia is the headline.
tap to flip →
Side Effects
Hypoglycemia (only class that does this hard). Weight gain. Skin reactions. The only oral that works in fasting state · which is exactly why it crashes sugar.
Watch Out
Elderly. CKD (drug accumulates). Skipped meals. Glyburide is the worst offender for prolonged hypoglycemia.
Board Trap
Elderly woman, kidney function dropped, found altered with glucose 38. The med list says glipizide. That's your answer · not sepsis, not stroke. Sulfonylurea + CKD = crash.
WEIGHT NEUTRAL · MEH
DPP-4 Inhibitors
−gliptin
sitagliptin, saxagliptin, linagliptin
Block DPP-4DPP-4 is the enzyme that chews up GLP-1 and GIP within minutes after a meal. Block the enzyme → the natural incretins live longer → more insulin (only when glucose is high). → GLP-1 and GIP last longer → glucose-dependent insulin release.
Glucose-dependent = no hypoglycemia. Weight neutral. A1C drop is modest (~0.5-0.7%).
tap to flip →
Side Effects
Upper respiratory infections. Headache. Pancreatitis (rare). Joint pain. Generally well tolerated.
Mortality?
No proven CV mortality benefit. Just lowers glucose.
Board Trap · SaxagliptinSaxagliptin is linked to heart failure hospitalizations (SAVOR-TIMI trial). If the stem has T2DM + HF and a −gliptin, saxagliptin is the trap answer.
Personal or family history of medullary thyroid cancer or MEN2 · black box warning.
Board Trap
T2DM + ASCVD (post-MI, stroke, PAD) → the right answer is almost always a −tide. Choosing a sulfonylurea here = strike out.
SAVES LIVES · HF + CKD
SGLT2 Inhibitors
−flozin
empagliflozin, dapagliflozin, canagliflozin
Block SGLT2SGLT2 sits on the proximal tubule and reabsorbs ~90% of filtered glucose. Block it and the kidney dumps glucose into urine. Less reabsorption, less plasma glucose, plus osmotic diuresis. in proximal tubule → glucose pees out. Modest A1C drop, big mortality wins.
Cuts HFrEF mortality (EMPA-REG, DAPA-HF). Slows CKD progression. Now used in HF even WITHOUT diabetes.
Fournier's gangrene · necrotizing fasciitis of the perineum. Rare, deadly, and a favorite stem element.
Board Trap
T2DM + HFrEF or CKD → reach for −flozin. T1DM with abdominal pain on a flozin and glucose 180? Euglycemic DKA · check ketones, don't miss it.
CAREFUL · HF CONTRAINDICATED
TZDs
−glitazone
pioglitazone, rosiglitazone (off market)
PPAR-γ agonistPPAR-gamma is a nuclear transcription factor in fat cells. Activate it and you upregulate genes that improve insulin signaling and shift fat storage to safer subcutaneous depots. Slow effect · weeks to kick in. → reprograms adipose + muscle to use insulin better.
Kidneys retain salt and water. Result: edema, weight gain, decompensated HF.
tap to flip →
Side Effects
Fluid retention, weight gain, increased fracture risk (especially women), bladder cancer signal (pioglitazone, controversial), worsened HF.
Don't Give To
Heart failure · absolute contraindication for NYHA III/IV. Rosiglitazone was pulled for CV risk; pioglitazone survived but stays cautious.
Board Trap
T2DM + edema or T2DM + HF on the stem? Stop the −glitazone, never start it. This is the cleanest contraindication in clinical practice.
⚠
THE QUICK SUFFIX MAP
−tide/−glutide = GLP-1 agonist (saves lives in ASCVD).
−flozin = SGLT2 inhibitor (saves lives in HF + CKD).
−gliptin = DPP-4 inhibitor (does nothing for mortality).
−glitazone = TZD (NEVER in HF).
−ide/−izide = sulfonylurea (hypoglycemia machine).
MEMORY HOOKS
Three Lines, Three Drugs
Tap each card to unblur. These are the lines you say to yourself the second the stem mentions one of these classes.
🧠
Metformin
Metformin = AMPK activator → decreases hepatic gluconeogenesis → no hypoglycemia. Contraindicated when eGFR < 30 and around IV contrast (hold 48h). Lactic acidosis is the lethal but rare worst case.
tap to reveal
🫕
SGLT2 Inhibitors
−flozin (empagliflozin, dapagliflozin) = glucose pees out in urine → UTI + yeast risk + euglycemic DKA (even with normal glucose, watch ketones in T2DM). Cuts HF and CKD mortality.
tap to reveal
💉
GLP-1 Agonists
All end in −glutide (liraglutide, semaglutide) = weight loss + CV mortality benefit + nausea. Glucose-dependent insulin release means no hypoglycemia. Black box for medullary thyroid cancer / MEN2.
tap to reveal
THE BIG QUESTION
Who Actually Saves Lives?
Tap every class you think has proven cardiovascular mortality benefit in T2DM. Confetti when you nail it. Wrong picks shake.
Tap the classes that cut CV mortality. Skip the ones that just lower glucose.
🏆Two classes save lives. GLP-1 agonists (LEADER · liraglutide, SUSTAIN-6 · semaglutide) reduced CV death in ASCVDASCVD = atherosclerotic CV disease. Anyone with prior MI, stroke, PAD, or significant carotid/coronary disease. clinical medicine love stems with "had MI 2 months ago.". SGLT2 inhibitors (EMPA-REG, DAPA-HF) cut HF + renal mortality and slow CKD. Everything else is glucose-only.
T2DM MANAGEMENT TREE
Walk the Algorithm
Newly diagnosed T2DM. Each step gates the next. Pick the answer you'd choose on the clinical medicine.
Q1 What is the first-line drug for newly diagnosed T2DM?
Metformin first. Cheap, weight-neutral, no hypoglycemia, modest CV signal. Start unless eGFR < 30 or contrast on the schedule. Hold 48h around IV contrast or major surgery.
Not first-line. Sulfonylureas drop A1C fast but cause hypoglycemia and have no mortality benefit. Reserve for cost-only situations. The right answer is metformin.
Only if A1C > 10 or symptomatic hyperglycemia at diagnosis. Otherwise start metformin. Insulin from day one is reserved for very high A1C or DKA-leaning presentations.
Great drug, wrong order. GLP-1 agonists are excellent add-ons (especially with ASCVD or obesity), but clinical medicine still want metformin first unless contraindicated.
Q2 Three months in on metformin, A1C still 8.0%. The patient had an MI 6 months ago. What do you add?
GLP-1 agonist. Recent MI = ASCVD · LEADER (liraglutide) and SUSTAIN-6 (semaglutide) cut CV death in this exact population. Bonus: weight loss. Skip if family history of medullary thyroid ca or MEN2 → pivot to SGLT2i.
Wrong tool. Sulfonylureas just lower A1C and cause hypoglycemia. With proven ASCVD on the chart, you have one shot to actually reduce CV death · spend it on a −tide.
Avoid. Post-MI patients have stunned myocardium and are HF-prone. TZDs cause salt and water retention and can decompensate them. Use a GLP-1 agonist.
Safe but lazy. DPP-4i won't hurt him but won't extend his life either. The mortality-proven choice in T2DM + ASCVD is a −tide.
Q3 Different patient: T2DM + HFrEF (EF 30%) + eGFR 45. A1C 8.4% on metformin. Best add-on?
SGLT2 inhibitor. EMPA-REG and DAPA-HF showed empagliflozin and dapagliflozin cut HF hospitalizations and CV mortality · even in non-diabetic HF. Bonus: slows CKD progression (DAPA-CKD). One drug, three benefits.
Reasonable but not best. GLP-1 helps ASCVD; SGLT2i is the dedicated HF and CKD lifesaver. With HFrEF + CKD on the stem, −flozin wins.
Contraindicated. TZDs in HFrEF = decompensation. Absolute no-go for NYHA III/IV.
Worst choice. Glyburide accumulates with eGFR 45 → prolonged hypoglycemia. Plus no HF or CKD benefit. SGLT2i is the answer.
Q4 Newly diagnosed T2DM patient walks in with A1C 11.4%, polyuria, blurry vision, ketones negative. What now?
Combo therapy or insulin from the start. A1C > 10 with symptoms means glucotoxicity is shutting down beta cells. ADA: start dual therapy (metformin + a second agent) or basal insulin immediately. Once glucose comes down, beta cell function often recovers and you can de-escalate.
Not aggressive enough. A1C > 10 with symptoms won't reach goal on metformin alone. You'll waste 3 months and the patient stays glucotoxic. Start combo or insulin now.
Symptomatic at A1C 11.4 = pharmacotherapy now. Lifestyle alone is for prediabetes or A1C 6.5−7.5 without symptoms. Don't let glucotoxicity ride.
Not the move. Sulfonylurea monotherapy at A1C 11.4 will crash beta cells faster and won't get to goal. Combo or insulin.
💭
THE 3-LINE clinical medicine RECIPE
Step 1: Metformin first (unless eGFR < 30 or contrast). Step 2: Not at goal? Add a mortality-proven drug · GLP-1 (ASCVD) or SGLT2i (HF/CKD). Step 3: A1C > 10 with symptoms? Start combo or insulin from day one.
DECISION TREE
clinical medicine Algorithm: Add a Drug
Patient is on metformin and still > goal. Walk the questions in order. Tap each branch.
Q1 Does the patient have ASCVD (prior MI, stroke, or PAD)?
Add a GLP-1 agonist (liraglutide or semaglutide). LEADER and SUSTAIN-6 showed CV mortality benefit. Bonus: weight loss in an obese diabetic. If MEN2 or medullary thyroid ca history → pivot to SGLT2i instead.
Move on. No ASCVD on the stem → check for HF or CKD next.
Q2 Heart failure (especially HFrEF) or CKD (eGFR 25−60)?
Add an SGLT2 inhibitor (empagliflozin or dapagliflozin). DAPA-HF and EMPA-REG showed mortality + hospitalization benefit. Works even in non-diabetic HF. NEVER add a TZD here · it'll worsen HF.
Move on. No HF or CKD → obesity is the next question.
Q3 Significant obesity (BMI > 30) or strong patient preference for weight loss?
GLP-1 agonist (preferred) or SGLT2i. Semaglutide gets ~10−15% weight loss. SGLT2i gets ~3−5%. Either beats sulfonylureas (weight gain) and TZDs (weight gain + edema).
Move on. No obesity driver → one last filter: hypoglycemia risk.
Q4 Elderly, CKD, or anyone where hypoglycemia would be catastrophic?
AVOID sulfonylureas. Pick DPP-4i, GLP-1, or SGLT2i · all glucose-dependent or non-insulin pathway. Glipizide in an 82yo with eGFR 32 = preventable hypoglycemic coma.
If cost is the only driver, sulfonylurea is acceptable but mortality-neutral. Counsel on hypoglycemia hard. Otherwise stay with mortality-proven choices.
⚠
THE 3-WORD CHEAT
Heart → tide. Kidney → flozin. Hypo → not −ide. Memorize that line and you'll get 80% of T2DM management questions right without reading the rest of the stem.
3 / 4
PROVE IT
Clinical Vignettes
10 questions in the pool, 6 shown per load. Answer order shuffles each time. Don't kill anybody.
4 / 4
START HERE
A 62-Year-Old Walks Into Your Clinic
He just had an MI three months ago. He's already on metformin. His A1C is still 8.2%. What do you add?
62yo man with T2DM (A1C 8.2% on metformin), recent NSTEMI 3 months ago, EF 45%, BP 128/76, eGFR 68, BMI 31. He asks: "Doc, what should we add next? My friend's on a sulfonylurea."
💡This page exists for ONE reason: when the test stem says "T2DM + heart attack/stroke/HF/CKD," you need to know which two drug classes to reach for · and which four are basically expensive Tic-Tacs that only lower a number on a lab.
1 / 4
Medically reviewed by Kaitlyn Cocuzzo, MD and Fatima Ali, DO · Last updated July 1, 2026 at 10:03 PM ET
Bone Wizardry is an independent educational resource for visual learning in the medical sciences. It is not affiliated with, endorsed by, or sponsored by any licensing or examination board, contains no real or recalled examination questions, and does not guarantee any educational or examination outcome.
